Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.